Geneva, July 14 -- International Clinical Trials Registry received information related to the study (ACTRN12625000697482) titled 'Doxycycline Use in Lung CancEr (DULCE)' on July 1.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Efficacy
Primary Sponsor: University of Technology Sydney
Condition:
Lung cancer
Lung cancer
Cancer - Lung - Non small cell
Intervention:
Doxycycline 100 mg tablet, 100 mg oral twice a day on the first day followed by 100 mg oral once a day for the next 27 days. Treatment period is 28 days total. Participants will receive doxycycline alongside their standard of care lung cancer treatme...